The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...
The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...
In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...
Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...
HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...
NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.
GlobalData on MSN14h
Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacksAfter Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...
The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...
Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, ...
Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S workforce.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback